Compared to rivastigmine capsule and patch without concurrent Vascular risk factors (VRF) what was the result of rivastigmine capsule and patch with concurrent Vascular risk factors (VRF) on incidence of adverse events?
Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, VRF.